| Lymphoma, Follicular
Brukinsa vs Lunsumio
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Brukinsa vs Lunsumio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLunsumio has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lunsumio but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Lunsumio
At A Glance
Oral
Once or twice daily
BTK inhibitor
IV infusion
Every 3 weeks
Bispecific CD20xCD3 T-cell engager
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Lymphoma, Follicular
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular Step-up dosing: 1 mg IV (Cycle 1 Day 1), 2 mg (Cycle 1 Day 8), 60 mg (Cycle 1 Day 15), 60 mg (Cycle 2 Day 1), then 30 mg every 3 weeks (Cycles 3+); 21-day cycles; administer as IV infusion over a minimum of 4 hours for initial doses.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=10%) CRS, fatigue, rash, pyrexia, headache, musculoskeletal pain, cough, pruritus, peripheral neuropathy, edema, diarrhea, nausea, dry skin, upper respiratory tract infection, chills, dizziness, insomnia, abdominal pain, arthralgia, dyspnea, skin exfoliation, urinary tract infection
Serious CRS, infections (sepsis, pneumonia, urinary tract infection, EBV viremia, COVID-19, upper respiratory tract infection), renal insufficiency, pyrexia, tumor flare
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engaging antibody that binds CD3 on T-cells and CD20 on lymphoma and B-lineage cells, activating T-cells to induce B-cell lysis and cytokine release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Lunsumio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Lunsumio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lunsumio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
LunsumioView full Lunsumio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.